PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 8647914-1 1996 Treatment of circulating human neutrophils with recombinant human granulocyte colony-stimulating factor (rhG-CSF) for 30 min augmented superoxide generation and chemotaxis induced by N-formylmethionyl-leucyl-phenylalanine (fMLP) in a dose dependent manner. N-Formylmethionine Leucyl-Phenylalanine 183-221 colony stimulating factor 3 Homo sapiens 66-103 11057460-6 2000 An increase in killing correlated with increases in production of superoxide (r = 0.96) and hydrogen peroxide (r= 0.97) by ALF neutrophils after incubation with 1,000 and 5,000 IU/ml of G-CSF when formylmethionylleucylphenylalanine (fMLP) was the stimulant. N-Formylmethionine Leucyl-Phenylalanine 197-231 colony stimulating factor 3 Homo sapiens 186-191 10953296-2 2000 Both G-CSF preparations similarly enhanced the N-Formyl-Met-Leu-Phe-induced-migration of human peripheral blood polymorphonuclear cells, but did not significantly affect the proliferation of human oral tumor cell lines (HSC-2, HSG). N-Formylmethionine Leucyl-Phenylalanine 47-67 colony stimulating factor 3 Homo sapiens 5-10 9310121-1 1997 We have demonstrated recently that methotrexate (MTX) inhibits superoxide generation and chemotaxis induced by N-formylmethionyl-leucyl-phenylalanine (fMLP) in neutrophils primed by granulocyte colony-stimulating factor (G-CSF). N-Formylmethionine Leucyl-Phenylalanine 111-149 colony stimulating factor 3 Homo sapiens 182-219 7684324-0 1993 Granulocyte colony-stimulating factor enhances the extracellular emission of reactive oxygen from neutrophils stimulated with formylmethionylleucylphenylalanine. N-Formylmethionine Leucyl-Phenylalanine 126-160 colony stimulating factor 3 Homo sapiens 0-37 8616019-1 1996 We evaluated the effects of high-dose recombinant human granulocyte colony-stimulating factor (rhG-CSF) therapy on N-formyl-methionyl-leucyl-phenylalanine (FMLP)-induced chemotaxis and superoxide (O2-) production in neutrophils from four patients with aplastic anaemia. N-Formylmethionine Leucyl-Phenylalanine 156-160 colony stimulating factor 3 Homo sapiens 56-93 7510873-9 1994 In vivo administration of G-CSF increased f-Met-Leu-Phe-triggered Ca2+ mobilization by neutrophils to 43% of control by mo 1 of G-CSF therapy and to 93% of control by mo 4, thus paralleling the improvements in O2- generation. N-Formylmethionine Leucyl-Phenylalanine 42-55 colony stimulating factor 3 Homo sapiens 26-31 7510873-9 1994 In vivo administration of G-CSF increased f-Met-Leu-Phe-triggered Ca2+ mobilization by neutrophils to 43% of control by mo 1 of G-CSF therapy and to 93% of control by mo 4, thus paralleling the improvements in O2- generation. N-Formylmethionine Leucyl-Phenylalanine 42-55 colony stimulating factor 3 Homo sapiens 128-133 7684324-1 1993 Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan. N-Formylmethionine Leucyl-Phenylalanine 155-189 colony stimulating factor 3 Homo sapiens 33-70 7684324-1 1993 Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan. N-Formylmethionine Leucyl-Phenylalanine 155-189 colony stimulating factor 3 Homo sapiens 72-77 7684324-1 1993 Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan. N-Formylmethionine Leucyl-Phenylalanine 191-195 colony stimulating factor 3 Homo sapiens 33-70 7684324-1 1993 Pretreatment of neutrophils with granulocyte colony-stimulating factor (G-CSF) enhanced luminol-dependent chemiluminescence emission by the stimulation of formylmethionylleucylphenylalanine (FMLP), opsonized zymosan, and zymosan. N-Formylmethionine Leucyl-Phenylalanine 191-195 colony stimulating factor 3 Homo sapiens 72-77 1384435-6 1992 Similar inhibition by the TK inhibitors and stimulation by the PKC inhibitors were also observed with formylmethionyl-leucyl-phenylalanine (FMLP)-induced superoxide (O2.-) generation by TNF-alpha- or G-CSF-primed PMN. N-Formylmethionine Leucyl-Phenylalanine 102-138 colony stimulating factor 3 Homo sapiens 200-205 1384435-6 1992 Similar inhibition by the TK inhibitors and stimulation by the PKC inhibitors were also observed with formylmethionyl-leucyl-phenylalanine (FMLP)-induced superoxide (O2.-) generation by TNF-alpha- or G-CSF-primed PMN. N-Formylmethionine Leucyl-Phenylalanine 140-144 colony stimulating factor 3 Homo sapiens 200-205 1720802-3 1991 G-CSF and GM-CSF alone stimulated neither superoxide production nor secretion, but both agents primed neutrophils for superoxide production stimulated by either N-formylmethionyl-leucyl-phenylalanine (FMLP) or ionomycin. N-Formylmethionine Leucyl-Phenylalanine 161-199 colony stimulating factor 3 Homo sapiens 0-5 1689190-3 1990 G-CSF also modulates multiple differentiated functions of human neutrophils, including enhanced oxidative metabolism in response to f-Met-Leu-Phe (f-MLP), increased antibody-dependent cell-mediated cytotoxicity (ADCC), and augmented arachidonic acid release in response to ionophore and chemotactic agents. N-Formylmethionine Leucyl-Phenylalanine 132-145 colony stimulating factor 3 Homo sapiens 0-5 1284233-7 1992 Both enhancement of formyl-methionyl-leucyl- phenylalanine (FMLP)-mediated O2.- generation and tyrosyl phosphorylation of some neutrophil proteins, i.e., 115, 108 and 84 kDa proteins, by HHPMN after treatment with G-CSF were strongly inhibited by cepharanthine in a concentration- and treatment-time-dependent manner. N-Formylmethionine Leucyl-Phenylalanine 60-64 colony stimulating factor 3 Homo sapiens 214-219